Aspire Pharmaceuticals

aspire-pharma.com

Aspire Pharmaceuticals is committed to manufacturing the highest quality nutritional soft gelatin supplements available in the market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

news image

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More

Business Insights

CLINCHOICE RAISES $150 MM SERIES E ROUND FINANCING, FURTHER STRENGTHENING ITS GLOBAL SERVICES CAPABILITIES

ClinChoice | July 05, 2022

news image

Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly Asia Ventures and Apricot Capital. Proceeds of the financing will be used to fund the Company's continued business expansion and innovative service offering worldwide. Recently, ClinChoice announced the successful completion of ...

Read More

Pharmacy Market

NOW AVAILABLE – XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25%, THE FIRST AND ONLY FDA APPROVED TREATMENT FOR DEMODEX BLEPHARITIS

globenewswire | August 28, 2023

news image

Tarsus Pharmaceuticals, Inc. whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that within weeks of FDA approval...

Read More

ULTRAGENYX PHARMACEUTICAL INC ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

Ultragenyx | July 03, 2020

news image

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life...

Read More
news image

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More
news image

Business Insights

CLINCHOICE RAISES $150 MM SERIES E ROUND FINANCING, FURTHER STRENGTHENING ITS GLOBAL SERVICES CAPABILITIES

ClinChoice | July 05, 2022

Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly Asia Ventures and Apricot Capital. Proceeds of the financing will be used to fund the Company's continued business expansion and innovative service offering worldwide. Recently, ClinChoice announced the successful completion of ...

Read More
news image

Pharmacy Market

NOW AVAILABLE – XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25%, THE FIRST AND ONLY FDA APPROVED TREATMENT FOR DEMODEX BLEPHARITIS

globenewswire | August 28, 2023

Tarsus Pharmaceuticals, Inc. whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that within weeks of FDA approval...

Read More
news image

ULTRAGENYX PHARMACEUTICAL INC ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

Ultragenyx | July 03, 2020

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life...

Read More

Resources

resource image

Pharma Tech

ValGenesis e-Logbook

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us